Ney Carter Borges: Randomized Trial of the Vascular Effects of Low-Dose Colchicine in High-Risk Type 2 Diabetes
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“Colchicine and Arterial Stiffness in High-Risk Type 2 Diabetes: A Randomized Trial Perspective
This randomized, double-blind, placebo-controlled trial evaluates the vascular effects of low-dose colchicine in patients with type 2 diabetes at elevated cardiovascular risk.
Over a 26-week period, 100 participants were assigned to colchicine 0.5 mg daily or placebo, with arterial stiffness assessed via carotid–femoral pulse wave velocity (cfPWV) as the primary endpoint.
The study demonstrates a statistically significant reduction in arterial stiffness progression with colchicine when adjusted for mean arterial pressure (ΔcfPWV minus 0.7 m/s; 95% CI minus 1.3 to minus 0.1; p equal to 0.03), suggesting a potential mechanistic link between anti-inflammatory therapy and vascular compliance improvement.
Notably, crude analyses without adjustment did not reach statistical significance, highlighting the hemodynamic interplay between blood pressure and arterial stiffness.
Secondary outcomes revealed no meaningful impact on 24-hour ambulatory blood pressure or albuminuria, indicating that colchicine’s vascular benefits may occur independently of systemic hemodynamic or renal effects.
Additionally, while a modest reduction in C-reactive protein was observed, other inflammatory biomarkers remained unchanged, suggesting a selective or limited anti-inflammatory modulation.
Clinically, these findings are relevant given that a 1.0 m/s increase in cfPWV is associated with approximately 15% higher cardiovascular risk.
Thus, the observed reduction may translate into meaningful long-term benefits, although this remains speculative.
In conclusion, colchicine appears to attenuate arterial stiffness progression in high-risk diabetic populations, reinforcing its role as a potential adjunctive strategy in residual cardiovascular risk reduction, pending confirmation from larger outcome-driven trials.”
Other posts featuring Ney Carter Borges on Hemostasis Today.
-
Jun 25, 2026, 19:32Javier M. Floren: A Blood Clot Is One of the Most Impressive Examples of Teamwork You’ll Ever See
-
Jun 25, 2026, 19:31Marcin Krzysztof Maniak: Linking Tissue Mechanics to Inflammation in Health and Disease
-
Jun 25, 2026, 19:29Deepak Rawat: A Diagnosis Like Immune Thrombocytopenia Changes Your Perspective
-
Jun 25, 2026, 19:27Srikanth R.: Don’t Ignore Your Health While Chasing Success
-
Jun 25, 2026, 19:27Jamie Nash: Delighted to Receive the BBTS Race and Sanger Award 2026
-
Jun 25, 2026, 15:56Wolfgang Miesbach: Building the Future of Gene Therapy – From Centre Readiness to Long-Term Patient Care
-
Jun 25, 2026, 15:46Amber Yates: Making a Meaningful Difference for People Living with Sickle Cell Disease
-
Jun 25, 2026, 15:43Nancy Cavey: Navigating Disability Benefits for Patients with Immune Thrombocytopenia
-
Jun 25, 2026, 15:28Damon Race: Pursuing Long-Term Expression in Hemophilia A Gene Therapy